CHRISTY KINSEY
Prescription History 1083083380
Nurse Practitioner in Chattanooga, TN

NPI Status: Active since September 17, 2015

Contact Information

6734 LEE HWY
CHATTANOOGA, TN
ZIP 37421
Phone: (423) 899-0431
Fax: (423) 499-9552

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHRISTY KINSEY, an active Nurse Practitioner specialist practicing in Chattanooga, TN. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 121 documented patient claims. Among these therapy options, the most frequently utilized medication is Montelukast Sodium, which accounts for 50 claims alone.

Medication Index


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 21.1
Days Supply 535
TN State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills84.3
Peer Average Days Supply2,114
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.7% less volume than the regional standard for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $790.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.91

State Avg Cost Per Claim

$50.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Levocetirizine Dihydrochloride

Generic Formulation: Levocetirizine DihydrochlorideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 35.0
Days Supply 1,050
TN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills69.9
Peer Average Days Supply2,055
Conservative Utilization

This provider writes prescriptions for this formulation 44.1% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $250.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.19

State Avg Cost Per Claim

$17.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levocetirizine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing. It is also used to relieve itching and hives. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction. Levocetirizine does not prevent hives or prevent/treat a serious allergic reaction (such as anaphylaxis). If your doctor has prescribed epinephrine to treat allergic reactions, always carry your epinephrine injector with you. Do not use levocetirizine in place of your epinephrine.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 50
30-Day Fills 102.7
Days Supply 3,080
TN State Average Benchmarks
Peer Average Claims71.0
Peer Average 30-Day Fills161.3
Peer Average Days Supply4,754
Conservative Utilization

This provider writes prescriptions for this formulation 29.6% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $712.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.26

State Avg Cost Per Claim

$16.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 34
30-Day Fills 46.0
Days Supply 1,380
TN State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills74.0
Peer Average Days Supply2,214
Conservative Utilization

This provider writes prescriptions for this formulation 38.2% less frequently than the standard regional baseline metric for practitioners inside TN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,021.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$882.98

State Avg Cost Per Claim

$875.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHRISTY KINSEY provides transparency into local medical care patterns within Chattanooga, TN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.